引 致 更 改 給 病 人 的 產 品 資 訊 的 藥 物 不 良 反 應 警 示
|
| |
| Canada: GnRH Agonists - heart-related risk in men treated for prostate cancer (English Only) |
| |
Health Canada is informing health professionals and patients about a possible increased risk of certain heart-related events in men being treated for prostate cancer with a type of prescription drug known as a Gonadotropin-Releasing Hormone (GnRH) agonists. There have been reports of heart attacks, stroke and heart-related deaths in patients treated with GnRH agonists for prostate cancer. Based on information collected from scientific literature, the risk appears to be low. When determining an appropriate prostate cancer treatment, physicians should weigh the benefits of Androgen Deprivation Therapy against the potential cardiovascular risk of GnRH agonists, along with any additional factors that may put a patient at increased risk for heart-related events. Patients receiving a GnRH agonist should be monitored for signs and symptoms suggestive of development of cardiovascular disease, and managed according to current clinical practice. The labelling for GnRH agonist drugs has been updated to add a warning on the potential increased risk of heart-related side effects.
Please refer to the following website in Health Canada for details:
http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_122-eng.php
In Hong Kong, a total of 11 GnRH agonists-containing products used in the treatment of prostate cancer are registered and are prescription-only medicines. The news has been released by the US FDA and was posted on the website of Pharmaceutical Service on 21 October 2010. A letter to inform healthcare professionals was issued on the same day. The matter was discussed in the meeting of Registration Committee of the Pharmacy and Poisons Board on 29 December 2010, and the Committee decided that products containing GnRH agonists for the treatment of prostate cancer should include the appropriate warning.
Ends/ Friday, September 9, 2011
Issued at HKT 12:30
|
| |
|
